Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $1.7 Million - $2.26 Million
-21,305 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $275,000 - $316,004
-3,191 Reduced 13.03%
21,305 $2.04 Million
Q2 2021

Aug 17, 2021

BUY
$89.43 - $102.27 $872,747 - $998,052
9,759 Added 66.22%
24,496 $2.38 Million
Q1 2021

May 18, 2021

SELL
$87.57 - $119.4 $645,303 - $879,858
-7,369 Reduced 33.33%
14,737 $1.43 Million
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $70,828 - $107,275
943 Added 4.46%
22,106 $1.91 Million
Q4 2019

Feb 13, 2020

BUY
$86.8 - $118.57 $226,895 - $309,941
2,614 Added 14.09%
21,163 $2.28 Million
Q3 2019

Nov 14, 2019

SELL
$83.82 - $101.5 $198,988 - $240,961
-2,374 Reduced 11.35%
18,549 $1.67 Million
Q2 2019

Jul 19, 2019

BUY
$72.24 - $91.27 $1.51 Million - $1.91 Million
20,923 New
20,923 $1.72 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Capital Impact Advisors, LLC Portfolio

Follow Capital Impact Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Impact Advisors, LLC with notifications on news.